Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166732 | 0.85 | ADORA2A (0.49) | HCRTR2GSK3BNOTUMFBP1ADORA2A | |
| SCHEMBL27900798 | 0.82 | HCRTR2 (0.43) | HCRTR2GSK3BNOTUMFBP1ADORA2A | |
| SCHEMBL9125394 | 0.82 | GSK3B (0.64) | HCRTR2GSK3BNOTUMFBP1ADORA2A | |
| SCHEMBL1969272 | 0.81 | ADORA2A (0.64) | HCRTR2GSK3BFBP1ADORA2AKDM4E | |
| SCHEMBL1167542 | 0.81 | FBP1 (0.47) | GSK3BFBP1ADORA2AKDM4EMEN1 | |
| SCHEMBL1166876 | 0.80 | GSK3B (0.50) | HCRTR2GSK3BFBP1ADORA2AMEN1 | |
| SCHEMBL5470802 | 0.79 | HCRTR2 (0.50) | HCRTR2GSK3BNOTUMFBP1ADORA2A | |
| SCHEMBL5474080 | 0.79 | LOXL2 (0.51) | HCRTR2GSK3BFBP1ADORA2AMEN1 | |
| SCHEMBL1166776 | 0.79 | GSK3B (0.49) | HCRTR2GSK3BFBP1ADORA2AMEN1 | |
| SCHEMBL6372051 | 0.78 | ADORA2A (0.60) | GSK3BFBP1ADORA2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR2 1/4885GSK3B 3215/4885NOTUM 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.